8-KLeadership Changes

REGENERON PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Oct 3, 2022)

Filed October 3, 2022For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) announced an important change to its Board of Directors through an 8-K filing on October 3, 2022. The company has elected Craig B. Thompson, M.D. as a new director, expanding the Board from 12 to 13 members. Dr. Thompson's appointment is effective immediately and he will serve until the 2023 Annual Shareholder Meeting. This addition signifies a potential strengthening of the Board's expertise, particularly in technology, as Dr. Thompson has also been appointed to the Board's Technology Committee. Investors should note that Dr. Thompson's compensation will align with the company's existing non-employee director compensation structure, as previously detailed in their proxy statement. There are no disclosed understandings or arrangements with other parties regarding his selection. This move is a governance update that could impact strategic oversight and technological direction for Regeneron.

Key Highlights

  • 1Regeneron Pharmaceuticals, Inc. appointed Dr. Craig B. Thompson as a new director to its Board of Directors.
  • 2The Board of Directors has been expanded from 12 to 13 members.
  • 3Dr. Thompson will serve as a director until the 2023 Annual Shareholder Meeting.
  • 4Dr. Thompson has been appointed to the Board's Technology Committee.
  • 5Dr. Thompson's compensation will follow the company's standard practices for non-employee directors.
  • 6There are no undisclosed arrangements or understandings related to Dr. Thompson's appointment.
  • 7The filing is an 8-K Current Report, indicating a significant event impacting the company's governance.

Frequently Asked Questions

While this 8-K filing does not provide detailed biographical information on Dr. Craig B. Thompson, M.D., his appointment to the Technology Committee suggests he brings expertise relevant to Regeneron's technological advancements and strategy. Investors may wish to consult Regeneron's proxy statement or Dr. Thompson's professional biography for further details on his qualifications.

The Board of Directors expanded from 12 to 13 members specifically to accommodate the appointment of the new director, Dr. Craig B. Thompson, M.D. This expansion was a necessary step to include him on the Board.

Dr. Thompson's appointment to the Technology Committee indicates a focus on leveraging his expertise in areas related to the company's technology and innovation strategy. For investors, this could signal a heightened emphasis on research and development, digital transformation, or other technology-driven initiatives within Regeneron.

Dr. Thompson will receive compensation for his services as a director in accordance with Regeneron's established compensation practices for its non-employee directors. The specifics of this compensation were previously detailed in the company's definitive proxy statement filed on April 21, 2022.